CIK 0001782223
- Emerging growth company
Pyxis Oncology, Inc.
Sign in to watch- Ticker
- PYXS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831160910
- Phone
- +1 617-221-9059
- Business address
- 321 HARRISON AVENUE, BOSTON, MA, 02118
- Open-market buys, last 90 days
- $0
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-24 | FLAVIN JOHN L Director | Grant or award · Stock Option (Right to Buy) | +45,867 | 45,867 | ||
| 2025-03-31 | FLAVIN JOHN L Director | Grant or award · Stock Option (Right to Buy) | +36,979 | $0.98 | $36K | 36,979 |
| 2024-03-26 | FLAVIN JOHN L Director | Grant or award | +35,219 | 413,015 | ||
| 2023-03-24 | FLAVIN JOHN L Director | Grant or award | +139,355 | 377,796 | ||
| 2022-03-31 | FLAVIN JOHN L Director | Grant or award | +66,831 | 238,441 | ||
| 2021-10-13 | FLAVIN JOHN L Director | Conversion | +2,388 | 171,610 | ||
| 2021-10-13 | FLAVIN JOHN L Director | Conversion · Series B Convertible Preferred Stock | −15,190 | 0 | ||
| 2021-10-07 | FLAVIN JOHN L Director | Grant or award · Stock Option (Right to buy) | +42,191 | 42,191 |
Page 1 of 1 · 8 trades